Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > SNL "Blocking it out for Christmas" Tribute to Roche Wine
View:
Post by Noteable on Dec 11, 2022 3:16pm

SNL "Blocking it out for Christmas" Tribute to Roche Wine

Timestamp: 3:45

https://www.nbc.com/saturday-night-live/video/blocking-it-out-for-christmas-cold-open/NBCE027909859
Comment by Noteable on Dec 11, 2022 3:39pm
SNL "Science Room" https://www.nbc.com/saturday-night-live/video/science-room-with-steve-martin-and-martin-short/NBCE028421930
Comment by Noteable on Dec 12, 2022 2:08pm
"Roche’s leadership shuffle continued on Monday with the departure of pharma sector CEO Bill Anderson. Anderson, formerly the boss of Roche subsidiary Genentech, took over as pharma CEO in 2019. But this year, the sector’s fortunes declined with several clinical setbacks. Anderson is leaving at the end of this year to “pursue other opportunities,” the company said in a release." " ...more  
Comment by Noteable on Dec 12, 2022 2:16pm
Roche’s immuno-oncology star Tecentriq disappointed in a lung cancer trial along with Exelixis and Ipsen’s Cabometyx, which was another in a series of disappointments for the combo, as was posted several days ago.
Comment by Noteable on Dec 12, 2022 2:35pm
Roche is a family-owned business that can't seem to wean itself off its family's history in pharmaceuticals.
Comment by TMAZZ21 on Dec 12, 2022 2:41pm
Okay Noteable so your all in with 100 shares x 265 pennies = 26,500 pennies If we see $10 soon, You will have made into the six figures = 100,000 pennies
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities